Rahul Lakhotia

10PUBLICATIONS
12CO-AUTHORS
Molecular targetsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Radiation therapyInfant and child health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Mar 04, 2026
A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma.

Max J Gordon, Milos D Miljkovic, Paige Milhon

|Oct 31, 2025
Enitociclib (VIP152), venetoclax and prednisone in relapsed or refractory aggressive non-Hodgkin lymphoma.

Max J Gordon, Rahul Lakhotia, Stefania Pittaluga

|Jun 16, 2025
The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas.

Rahul Lakhotia, Christopher Melani, Stefania Pittaluga

|Feb 03, 2025
Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas.

Rahul Lakhotia, Christopher Melani, Kieron Dunleavy

|Jun 30, 2023
Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R.

Rahul Lakhotia, Kieron Dunleavy, Jeremy S Abramson

|Apr 04, 2022
Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?

Rahul Lakhotia, Christopher Melani, Mark Roschewski

Pageof 2

Frequent Collaborators

7 joint publications

Christopher Melani

6 joint publications

Mark Roschewski

5 joint publications

Stefania Pittaluga

4 joint publications

Elaine S Jaffe